Navigation Links
Omeros Corporation Reports Third Quarter 2013 Financial Results
Date:11/7/2013

SEATTLE, Wash., Nov. 7, 2013 /PRNewswire/ --

  • Received $17.4 million in cash in October 2013
  • Total operating expenses in 3Q 2013 were $13.6 million including $3.2 million in non-cash expenses compared to $13.3 million including non-cash expenses of $2.1 million in 2Q 2013
  • U.S. and European regulators accepted Omeros' OMS302 marketing applications for review
  • OMS824 and OMS721 Phase 1 clinical programs generated positive data
  • Increased the number of unlocked orphan GPCRs to 52
  • Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial results for the third quarter of 2013.

    "Throughout the third quarter of 2013, we continued to make significant strides in development across our pipeline," stated Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "For OMS302, the marketing applications were accepted for review by both the FDA and EMA, and the market launch is planned for the second half of 2014. Our OMS824 program for the treatment of cognitive disorders was granted orphan drug designation by the FDA, generated positive Phase 1 clinical trial results, began enrollment in a Phase 2 trial in patients with schizophrenia and is now initiating a Phase 2 trial in Huntington's disease. OMS721, our MASP-2 inhibitor, entered a Phase 1 clinical trial from which we reported positive data today, and a Phase 2 trial to evaluate the molecule's efficacy and safety in patients with thrombotic microangiopathies is planned for early 2014. Preclinically, our GPCR platform continued to identify functionally active compounds against an
    '/>"/>

    SOURCE Omeros Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common Stock
    2. Omeros to Present at the 12th Annual Needham Healthcare Conference
    3. Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
    4. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
    5. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
    6. Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
    7. Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
    8. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
    9. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2014 Financial Results
    10. Attention Amarin Corporation plc Investors: Amarin Corporation plc Misled Investors According to a Newly Filed Class Action
    11. General Patent Corporation Chairman and CEO Alexander Poltorak Joins Spherix Board Industry veteran and authority on patent law and valuation joins Spherix as director
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2015)... 2015 AACC welcomed thousands of medical ... Annual Meeting & Clinical Lab Expo in ... meeting showcased revolutionary advancements in clinical testing technology ... providers to diagnose patients quickly and accurately and ... As of Wednesday, July 29, more ...
    (Date:7/30/2015)... ... July 30, 2015 , ... The 2015 Market Research ... on the current state of the global Propanol market with a focus on the ... Eastman, Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, LG Chem ...
    (Date:7/30/2015)... 30, 2015   Aratana Therapeutics, Inc . ... focused on the licensing, development and commercialization of ... that its strategic partner VetStem Biopharma, Inc. has ... of AT-016, an adipose-derived allogeneic stem cell product ... osteoarthritis pain in dogs. The double-blinded, ...
    (Date:7/30/2015)... Denmark , July 30, 2015 ... biotechnology company that applies its innovative TransCon technology ... positive top-line results from a six-month Phase 2 ... once-weekly TransCon Growth Hormone in 53 treatment-naïve, pre-pubertal ... "We are extremely pleased with the top-line ...
    Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
    ... noses modeled after biological olfaction, the challenge has been ... requisite combinatorial complexity to detect odors in the real ... be manufactured with exact chemical precision and reproducibility. , ... open-access journal PLoS Biology, Joel White, Mary AtKisson, John ...
    ... Fla., Jan. 22 The Delaware Court of,Chancery today ... brought by a,stockholder of Cryo-Cell International Inc. (OTC Bulletin ... of stockholders held,on July 16, 2007. The court ordered ... a special stockholders meeting to be held on March ...
    ... Hospitals and healthcare,institutions are challenged to devise ... take place while maintaining Environment of Care,(EC) ... these challenges is,available for download at: ... "Infection Control in the Healthcare,Environment During Construction," ...
    Cached Biology Technology:Special Stockholders Meeting to Elect Directors Set for March 4, 2008 2White Paper Details Infection Control Challenges Hospitals Must Address During Construction 2
    (Date:7/8/2015)... N.J. and NEW YORK , July 8, ... Guidepoint today announced BD & Guidepoint Mentor, ... with free access to Guidepoint,s expert network services. ... are developing cutting-edge technologies to improve healthcare delivery and ... research manager, each start-up entrepreneur will be able to ...
    (Date:7/7/2015)... VIEW, Calif. , July 7, 2015 /PRNewswire/ ... biometrics market, Frost & Sullivan recognizes Credence ID, ... Sullivan Entrepreneurial Company of the Year Award. ... suite to aid in its mission of offering ... under-recognized populations globally. As Credence ID was formed ...
    (Date:7/2/2015)... 2015 Fingerprint Cards has received an ... FPC1155 from the distributor World Peace Industrial Group (WPI), part ... Asia . Deliveries are planned to take ... used by smartphone manufacturers in Asia . ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ...
    Breaking Biology News(10 mins):BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2
    ... of eleven organisations, coordinated by the Institute of Environmental ... (ICTA-UAB), will train 18 researchers in Political Ecology over ... European project ENTITLE. The initiative aims to create an ... build a stable collaboration on Doctoral studies that takes ...
    ... different dosages of vitamin D supplementation in breastfed infants, ... range recommended by some pediatric societies. However, all dosages ... recommended by the Institute of Medicine, according to a ... , a theme issue on child health. Hope ...
    ... delivering tumor cell-killing enzymes in a way that protects the ... In their study in mBio , the online open-access ... protein packages that can deliver an enzyme called PEIII to ... to the enzyme, they were able to protect it from ...
    Cached Biology News:European support for the first network of research and training in political ecology 2European support for the first network of research and training in political ecology 3Optimal vitamin D dosage for infants uncertain 2Optimal vitamin D dosage for infants uncertain 3Protein improves efficacy of tumor-killing enzyme 2
    Mouse Axl MAb (Clone 175128)...
    Mouse GDF-8 Propeptide Affinity Purified Polyclonal Ab...
    ... D. Dawbarn and S.J. Allen (1995) ... date reviews by world authorities on current ... for Alzheimer's disease. Several major advances have ... understanding of this disease. Topics include molecular ...
    One-step, microplate or cuvet, colorimetric, linear detection range 0.1 mg/dL to 100 mg/dL. Procedure: 20 min....
    Biology Products: